Drug Profile
Anti-NY ESO 1 T-cell receptor mimic monoclonal antibody - Pure MHC
Alternative Names: Anti-NY-ESO1 T-cell receptor mimic monoclonal antibody - Pure MHC; Anti-NY-ESO1 TCRm monoclonal antibody - Pure MHCLatest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Pure MHC
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 17 Apr 2018 Pure MHC's Anti-NY ESO 1 T-cell receptor mimic monoclonal antibody is available for licensing as of 17 Apr 2018. http://puremhc.com/partnering-opportunities/
- 12 Jan 2016 Early research in Cancer in USA (unspecified route)